Rhea Chitalia

Abstract 3751: QVT Subscore: An interpretable radiomic panel of tumor vascularity reveals treatment-specific mechanisms-of-action (MoA) in NSCLC

Haojia Li, P. Mutha, Young Kwang Chae, Kai Zhang et autres

Abstract Background: Tumor angiogenesis drives treatment resistance by fostering an immunosuppressive microenvironment. VEGF inhibitors (VEGFi) target the vasculature, while immune checkpoint inhibitors (ICI) do not address this mechanism directly. Quantitative Vessel Tortuosity (QVT) Score is a radiomic biomarker of vascularity previously shown …

us (code pays fourni par la source)

QVT score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy

Young Kwang Chae, Vamsidhar Velcheti, Kai Zhang, Amogh Hiremath et autres

BACKGROUND: Immune checkpoint inhibitors (ICIs) improve survival in advanced non-small cell lung cancer (NSCLC), yet current biomarkers such as programmed death-ligand 1 (PD-L1) expression and response criteria (Response Evaluation Criteria in Solid Tumors, RECIST, V.1.1) align poorly with long-term survival. Radiomics has …

us, ca (code pays fourni par la source)

66 QVT Score, a radiomic biomarker of tumor vascularity, enables immune checkpoint inhibitor (ICI) outcome prediction and early survival assessment in NSCLC

Young Kwang Chae, Kai Zhang, Liam Il‐Young Chung, Amogh Hiremath et autres

Background Predicting ICI benefit relies primarily on PD-L1 expression, which is a poor one-dimensional measure and overlooks resistance mechanisms such as tumor angiogenesis. QVT is a radiomic approach for measuring abnormalities of the tumor-associated vasculature, which have been shown to be associated …

us (code pays fourni par la source)

QVT Score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy

Y.K. Chae, Vamsidhar Velcheti, Kai Zhang, Amogh Hiremath et autres

Abstract Background Immune checkpoint inhibitors (ICIs) improve survival in advanced non-small cell lung cancer (NSCLC), yet current biomarkers such as PD-L1 expression and response criteria (RECIST v1.1) align poorly with long-term survival. Radiomics has been proposed as a source of novel biomarkers, …

us (code pays fourni par la source)

Radiomic phenotypes of tumor angiogenesis compared with PD-L1 in pre-treatment prediction of outcomes across immunotherapy regimens in NSCLC: An external validation study.

Vamsidhar Velcheti, Young Kwang Chae, Kai Zhang, Il-Young Chung et autres

8581 Background: Tumor angiogenesis is critical to cancer progression and treatment resistance, as evidenced by the success of therapies targeting both immune activation and neoangiogenesis. Conventional biomarkers like PD-L1 unreliably predict long-term patient outcomes such as overall survival (OS). Quantitative Vessel Tortuosity …

us (code pays fourni par la source)

Effect of fusion of radiomic, pathomic, and clinical biomarkers on multi-scale tumor biology and OS stratification in HNSCC receiving standard of care (SOC).

Omid Haji Maghsoudi, Haojia Li, Lauren Brady, Kai Zhang et autres

6046 Background: SOC immunotherapy (IO) for head and neck squamous cell carcinoma (HNSCC) has limited efficacy with inadequate biomarkers (BMs), necessitating improved strategies. Routine radiology and pathology scans provide underutilized tumor data that can address this need. BMs built from these scans …

us (code pays fourni par la source)

MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial)

Kalina P. Slavkova, Ruya Kang, Anum S. Kazerouni, Debosmita Biswas et autres

Models using clinical and MRI-based radiomic features identified from ductal carcinoma in situ lesions improved prediction of disease upstaging at surgery compared with standard clinical information alone.

us (code pays fourni par la source)

Erratum for: MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial)

Kalina P. Slavkova, Ruya Kang, Anum S. Kazerouni, Debosmita Biswas et autres

5MO Novel radiologic phenotypes of chaotic tumor angiogenesis associated with poor ICI outcomes in NSCLC

Vamsidhar Velcheti, Rhea Chitalia, Carla Leibowitz, Kai Zhang et autres

VEGF and immune checkpoint inhibitor (ICI) combination treatments have recently shown efficacy in non-small cell lung cancer (NSCLC), highlighting the role of tumor vasculature in outcomes. Conventional biomarkers focus on genetic or immune factors, but overlook the vascular complexity of tumors. We …

us, ca (code pays fourni par la source)

Combining radiomic features with background parenchymal enhancement from DCE-MRI data for predicting treatment response in breast cancer

Kalina P. Slavkova, Eric A. Cohen, Rhea Chitalia, Snekha Thakran et autres

Our objective is to predict pathological complete response (pCR) outcome to neoadjuvent chemotherapy in breast cancer patients. We combine radiomic features with background parenchymal enhancement -- computed from standard-of DCE-MRI data from the ISPY-2 trial -- and model treatment outcome via multivariable …

Abstract PO3-28-10: MRI Radiomic phenotypes derived from the ECOG-ACRIN E4112 Trial to assess high-risk ductal carcinoma in situ

Kalina P. Slavkova, Ruya Kang, Vivian Belenky, Anum S. Kazerouni et autres

Abstract INTRODUCTION Ductal carcinoma in situ (DCIS) is a non-lethal pre-invasive breast cancer that can co-exist with invasive disease. Dynamic contrast-enhanced (DCE) MRI is sensitive for the detection of high-grade DCIS and invasive cancer while Oncotype DCIS Score is a 12-gene assay …

us, ru, Afrique du Sud (code pays fourni par la source)

56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma

Patrick Schöffski, Patricia LoRusso, Nobuyuki Yamamoto, Peter Reichardt et autres

Targeting the MDM2–p53 interaction represents a potential therapeutic option in liposarcoma. In an earlier analysis of this phase Ia/Ib study (NCT03449381), brigimadlin, a highly potent, orally available MDM2–p53 antagonist showed promising safety and efficacy in patients (pts) with advanced solid tumours including …

be, us, jp, de, at (code pays fourni par la source)